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ABSTRACT
Background The close relationship between joints and 
gut inflammation has long been known and several data 
suggest that dysbiosis could link spondyloarthritis (SpA) 
to inflammatory bowel diseases (IBD). The introduction of 
biological drugs, in particular tumour necrosis factor inhibitors 
(TNFi), revolutionised the management of both these diseases. 
While the impact of conventional drugs on gut microbiota is 
well known, poor data are available about TNFi.
Aim To investigate the impact of TNFi on gut microbiota.
Methods We evaluated 20 patients affected by 
enteropathic arthritis, naïve for biological drugs, treated 
with TNFi at baseline and after 6 months of therapy. All 
patients followed a Mediterranean diet. Patients performed 
self- sampling of a faecal sample at baseline and after 6 
months of therapy. NGS- based ITS and 16S rRNA gene 
sequencing was performed, followed by the taxonomic 
bioinformatics analysis.
Results After 6 months of therapy, we detected a 
remarkable increase in Lachnospiraceae family (Δ +10.3, 
p=0.04) and Coprococcus genus (Δ +2.8, p=0.003). 
We also noted a decreasing trend in Proteobacteria 
(Δ −8.0, p=0.095) and Gammaproteobacteria (Δ −9, 
p=0.093) and an increasing trend in Clostridia (Δ +8.2, 
p=0.083). We did not find differences between TNFi 
responders (SpA improvement or IBD remission achieved) 
and non- responders in terms of alpha and beta diversity.
Conclusions Our findings are consistent with the hypothesis 
that TNFi therapy tends to restore the intestinal eubiosis.
INTRODUCTION
Enteropathic arthritis is included in a cluster 
of inflammatory joint diseases,1 according to 
the European Spondyloarthropathy Study 
Group classification criteria.2 Patients with 
enteropathic spondyloarthritis (SpA) show 
clinical features of axial3 and peripheral4 SpA, 
associated with either Crohn’s disease (CD) 
or ulcerative colitis (UC). The exact patho-
genetic mechanisms linking gut inflamma-
tion with joint inflammation are still unclear, 
although shared genes and environmental 
factors might be involved.5
The role of microbiota in host health is 
well established, mainly through the main-
tenance of the mucosal integrity and anti- 
inflammatory immune response6–8; therefore, 
it is not surprising that dysbiosis, defined as 
the loss of microbiome diversity and compo-
sition in an individual, can promote autoim-
mune diseases.
Pieces of evidence regarding dysbiosis and 
SpA have been published 9–19 and data would 
suggest a link between SpA and inflammatory 
bowel diseases (IBD).9 20 21
Key messages
What is already known about this subject?
 ► To date, the manipulation of the intestinal microbi-
ota is considered pivotal for the cure or control of 
several pathologies, which are sustained and fuelled 
by dysbiosis.
 ► Scarce data are currently available about dysbiosis 
and inflammatory arthritis.
 ► The impact of microbiota on rheumatic diseases and 
the effect of tumour necrosis factor (TNF) treatment 
on microbiota is inadequately investigated and not 
still completely understood.
What does this study add?
 ► To our knowledge, this is the first study that eval-
uates the impact of anti- TNFs on the microbiota in 
patients with enteropathic spondyloarthritis.
How might this impact on clinical practice or 
further developments?
 ► Our study contributes to reinforce the hypothesis 
that the therapy with anti- TNF alpha can affect mi-
crobiota by restoring intestinal eubiosis.
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The introduction of biological drugs, in particular 
tumour necrosis factor inhibitors (TNFi), revolutionised 
the handling of enteropathic SpA.22–26 Infliximab and 
adalimumab are approved for the treatment of CD and 
UC, and the 2019 recommendations encourage the use 
of these two TNFi monoclonal antibodies in patients with 
seronegative SpA and coexisting IBD.27
While the impact of TNFi on restoring gut perme-
ability is well known,28–30 unsatisfactory data are avail-
able on microbiota and TNFi. Data acquired on animals 
would suggest that TNFi can restore gut permeability and 
microbiota.31 Few studies about the impact on TNFi on 
microbiota in humans affected by IBD or SpA would indi-
cate a role of TNFi in restoring eubyosis32–34; yet, data on 
enteropathic SpA are still not available.32 33
Our study aimed to investigate the impact of TNFi on 
gut microbiota as well as the association of microbiome 
characteristics with inflammatory parameters in a popu-
lation of enteropathic arthritis patients, who were treated 
with either adalimumab or infliximab.
MATERIALS AND METHODS
Patients recruitment and study design
Twenty patients were recruited at the Rheumatologic- 
Gastroenterologic Diseases clinic in Città della Salute 
e della Scienza di Torino, Italy, from June 2017 to 
December 2018.
Inclusion criteria comprised: patients of age greater than 
18 years old and capable of providing informed consent 
before study participation; patients on a typical Mediterra-
nean diet; CD or UC diagnosis in patients fulfilling criteria 
for axial or peripheral SpA (ASAS 20093 35); patients able 
to perform the sample’s test after appropriate training as 
indicated in the BMR Genomics protocol; patients naïve 
to TNFi, and treated for arthritis, IBD or both, according 
to current guidelines for rheumatic disease36 and IBD37 38; 
stable concomitant treatment in the previous 3 months and 
for all the duration of the study.
Exclusion criteria were: history of major bowel resec-
tion; history of minor bowel resection or digestive stoma 
in the previous 5 years; any contra- indication to TNFi 
therapy; refusal to sign the informed consent; linguistic 
or cognitive difficulties that did not allow a full under-
standing of the consent form process; pregnancy or 
breastfeeding.
Clinical history, physical examination, instrumental 
examinations, biochemical examination including C 
reactive protein (CRP), erythrocyte sedimentation rate 
(ESR), HLA- B27 and faecal calprotectin at the baseline 
and after 6 months were performed.
All patients were screened for Hepatitis B Virus (HBV), 
Hepatitis C Virus (HCV) and Mycobacterium tuberculosis 
(HBsAg, HBcAb, HBsAb; HCV- Ab; quantiferon- TB gold 
assay, chest X- ray) before starting biologicals, as per 
normal clinical practice. Faecal samples were collected for 
every participant: the first within 24 hours before starting 
TNFi, while the second after 6 months of therapy. After 
the discussion at the interdisciplinary rheumatic/gastro-
enteric board, treatment decisions were made based on 
clinical requirements.
All participants filled out a food daily diary to verify 
the Mediterranean diet, the absence of food intolerance 
with the consequent bias due to food restrictions, and the 
intake of drugs different from standard therapy.
The design of the prospective study did not affect the 
treatment or other clinical actions. Patients were naïve 
to TNFi treatment or other biologicals. TNFi included 
infliximab and adalimumab.
The study was approved by the ethics committee and 
subjects provided prior written informed consent.
Samples collection, processing and analysis
Faecal samples were collected in 2 mL faeces collection 
tubes with screw caps, filled with DNA- stabilisation buffer 
provided by BMR Genomics, and stored at −80°C until 
further use. All patients were trained for faecal sample 
collection, to reduce as much as possible the sample 
contamination; all samples complied with quality control.
The processing performed through metagenomic 
NGS (next- generation sequencing or sequencing in 
parallel) by BMR Genomics laboratories included the 
amplification of the V3 and V4 regions of the 16S- gene 
using universal primers according to Takahashi et al39 
followed by sequencing on the Illumina MiSeq platform 
(San Diego, California, USA) in the Paired- End 2×300 bp 
format and the standard bioinformatic taxonomic anal-
ysis of the 16S NGS.
Patient assessment
All patients were scheduled for biological therapy and 
received the treatment at least until week 24. Clinical 
disease indices were evaluated at baseline and the end 
of the study using: (i) Visual Analogue Scale to measure 
pain and disease activity in all patients; (ii) Bath Anky-
losing Spondylitis Disease Activity Index (BASDAI) for 
axial involvement; (iii) Clinical Disease Activity Index 
(CDAI); (iv) Health Assessment Questionnaire- Disability 
Index (HAQ- DI) for peripheral involvement; (v) Harvey- 
Bradshaw Index for CD (HBI)40 or partial Mayo (pMAYO) 
score for UC. The BASDAI clinical response was defined 
as a BASDAI <4.41 The improvement in HAQ- DI was 
defined as a minimum clinically important difference of 
0.22.42 Responders in the HBI for CD were defined by 
a decrease in the HBI score greater than or equal to 2 
(or HBI ≤4 at 6 months), corticosteroid- free therapy. For 
patients with UC remission was defined as the reduction 
of the pMAYO43 by at least two points, or final score ≤1, 
in the absence of corticosteroids.
Statistical analysis
Continuous characteristics were presented as median and 
IQR or mean±SD. For proportions, absolute and relative 
frequencies were reported.
Mc- Nemar test was performed to analyse qualitative 
differences, while Wilcoxon test was applied to analyse 
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Univariate regression models were implemented to test 
the microbiota differences between baseline and after 
6 months (linear model for clinimetric variables and 
logistic model for IBD success or SpA improvement).
A p value <0.05 was considered to indicate statistical 
significance. The analysis was performed using R Statis-
tical Software (Foundation for Statistical Computing, 
Vienna, Austria).44
Alpha diversity45 is a measure of the diversity of species 
within an ecosystem or sample; it is expressed by the 
number of species or Operational Taxonomic Units 
(OTU) observed in the sample, which is a measure of 
species richness and evenness in that sample. Alpha 
diversity was measured through the Simpson’s Diversity 
Index (equation 1) and Shannon- Wiener Diversity Index 
(equation 2) from the OTU occurrence matrix.46
The Simpson’s Diversity Index (D) was calculated using 
the following equation:
 













in which ni is the total number of OTUs in a partic-
ular species, while N is the total number of OTUs in all 
species.
The Shannon- Wiener Diversity Index (H) was calcu-








in which pi is ni divided by N.
Beta diversity45 is a measure of the diversity of species 
between two or more ecosystems or samples; it is 
expressed as the total number of unique species among 
the samples which are under comparison. Beta diver-
sity therefore provides the variability of observed taxa 
among samples. The beta diversity Index was calculated 
using the PAST software by inputting the OTU occur-
rence matrix.46 Principal Coordinates Analysis (PCoA) 
plots of Beta diversity were performed using the Bray- 
Curtis similarity index, with the transformation expo-
nent equal to 2. To test the significance between groups, 
one- way analysis of similarity (ANOSIM) was carried out 
using Bray- Curtis distances, with the number of permu-
tation set to 9999.
RESULTS
Twenty patients met inclusion criteria and were accepted 
to participate in the study. Informed consent was obtained 
from study participants.
The overview of patient characteristics is summarised 
in table 1.
Surgery (ileocecal resection) had been performed in 9 
(45%) patients before the last 5 years.
At the baseline 90% of patients received mesalazine, 
60% of patients took systemic corticosteroids and 20% 
took an immunosuppressant (azathioprine). All patients 
followed a Mediterranean diet.
Clinical outcomes
After 6 months of therapy, no patient discontinued TNFi 
due to adverse events; 100% of patients achieved clinical 
IBD remission, while the success of the therapy (corticos-
teroids free) was only achieved in 65% of patients (13 out 
of 20). The improvement of rheumatic manifestations 
was reached in 70% of patients.
CRP decreased from a median value of 8.2 mg/L 
(4.8–20.8 mg/L) at T0 to a median value of 2.9 mg/L 
(1–4 mg/L) at T6 (p=0.001). Similarly, the ESR decreased 
from a median value of 21.5 mm/hour (10.8–34 mm/
hour) at T0 to 11 mm/hour (7.8–21 mm/hour) at T6 
(p=0.003). Calprotectin decreased from a median value 
of 207.5 µg/g (125.5–446.2 µg/g) at T0 to a median value 
of 81 µg/g (50–197.2 µg/g) at T6 (p=0.004).
As regards clinimetry, we noticed a BASDAI decrease from 
5.2 (4.1–5.6) to 2.8 (2.5–4.3, p=0.013), CDAI decrease from 
13 (10.5–16) to 7 (5.2–11, p=0.004) (see table 2).
Description of the microbiota composition and effect of TNFi 
on microbiota
The faecal microbiota at baseline was characterised 
by a large proportion of Firmicutes (43.6% (29.5–
53.8)) followed by Bacteroidetes (35.5% (19.1–50.3)), 
Table 1 Demographic and biometrics characteristics
Characteristics Value
Median age (IQR) 53 (43.8–61.5)
Sex, n (%)—male 12 (60)
Smokers, n (%) 4 (20)
Family history of RD/IBD, n (%) 3 (15)
Years of illness (years) 14.5 (1–38)
Arthritis, n (%)—PsA 1 (5)
Arthritis, n (%)—AS 8 (40)
Arthritis, n (%)—SpA 11 (55)
Axial, n (%) 10 (50)
Peripheral, n (%) 12 (60)
IBD, n (%)—Crohn’s 17 (85)
IBD, n (%)—UC 3 (15)
Skin involvement, n (%) 4 (20)
Eye involvement, n (%) 6 (30)
HLA- B27, n (%) 3 (15)
Endoscopic score, n (%)—1 2 (10)
Endoscopic score, n (%)—2 13 (65)
Endoscopic score, n (%)—3 5 (25)
Gut localisation, n (%)—E3 2 (10)
Gut localisation, n (%)—L1 8 (40)
Gut localisation, n (%)—L2 3 (15)
Gut localisation, n (%)—L3 6 (30)
Gut localisation n (%)—L4 1 (5)
AS, Ankylosing Spondylitis; IBD, inflammatory bowel diseases; 
PsA, Psoriatic Arthritis; RD, Rheumatic Disease; SpA, 
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Proteobacteria (12.6% (3.4–23.3)), Actinobacteria (0.8% 
(0.1–4.5)) (see figure 1).
We compared the global composition of the faecal 
microbiota between T0 and T6. After 6 months of therapy, 
we observed noteworthy differences among the family 
of Lachnospiraceae (Δ +10.3, p=0.04) and the genus of 
Coprococcus (Δ +2.8, p=0.003), as shown in figure 2. We 
also observed an increase in the proportion of unclassi-
fied phyla (figure 1, Δ +10.3, p=0.015).
Despite the absence of statistically significant 
differences, we observed a trend in Proteobacteria 
(Δ −9.0, p=0.087), Clostridia (Δ +8.2, p=0.083) and 
Gammaproteobacteria (Δ −9, p=0.093), Lachnospiraceae 
(Δ +9.4, p=0.044) and Dorea (Δ +1.2, p=0.059).
The univariate analysis for the comparison of relevant 
microbiota variables (outcome) between clinimetric 
variables (covariates) and the delta (T6- T0) exhibited a 
significant result only for CRP (p=0.033) (table 3).
The univariate analysis for the comparison between 
clinimetric variables (covariates) and the delta (T6- T0) 
of relevant microbiota variables (covariates) and the IBD 
success/SpA improvement outcome did not show any 
significant correlation (table 4).
Finally, we compared alpha (intra- sample) and beta 
(inter- sample) diversity among patients at baseline and 
after 6 months of therapy (online supplemental files 
1–6). We found a decrease of alpha diversity assessed by 
the Shannon- Weiner index in the class subgroup after 
therapy (figure 3). Comparing the responders group 
versus the non- responders one, we noted a meaningful 
reduction of alpha diversity determined by the Shannon- 
Wiener index only in the non- responder class group 
(figure 4) (online supplemental file 7); however, these 
results have not been confirmed when alpha diversity was 
assessed through the Simpson index (figure 5) (online 
supplemental file 8). When beta diversity was measured 
among population groups we did not identify differences 
either between T0 and T6 or between responders and 
non- responders.
Table 2 Comparison of clinical variables between baseline and T6 (6 months)
Clinical variables T0 T6 P value
Faecal calprotectin (μg/g)—median (IQR) 207.5 (125.5–446.2) 81 (50–197.2) 0.004
CRP (mg/L)—median (IQR) 8.2 (4.8–20.8) 2.9 (1–4) 0.001
ESR (mm/hour)—median (IQR) 21.5 (10.8–34) 11 (7.8–21) 0.003
VAS_pain—median (IQR) 50 (38.8–60) 35 (10–42.5) 0.001
VAS_disease—median (IQR) 50 (38.8–50) 37.5 (25–42.5) 0.006
HAQ—mediana (IQR) 0.6 (0.1–0.8) 0.2 (0.1–0.6) 0.004
BASDAI_score—median (IQR) 5.2 (4.1–5.6) 2.8 (2.5–4.3) 0.013
CDAI_activity—median (IQR) 13 (10.5–16) 7 (5.2–11) 0.004
IBD activity, n (%)—0 11 (55) 20 (100) 0.174
IBD activity, n (%)—1 6 (30) 0 (0)
IBD activity, n (%)—2 2 (10) 0 (0)
IBD activity, n (%)—3 1 (5) 0 (0)
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte 
sedimentation rate; HAQ, Health Assessment Questionnaire; IBD, inflammatory bowel diseases; VAS, Visual Analogue Scale.
Figure 1 Distribution of phylum at the baseline (T0) and 
after 6 months (T6).
Figure 2 Comparison between Lachnospiraceae and 
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DISCUSSION
The human gut microbiota is composed of approx-
imately 100 trillion bacteria, belonging to several 
hundreds of different species.47 More than 90% of all 
colonic bacteria belongs to four phyla in the Bacteria 
domain: primarily in Firmicutes and Bacteroidetes 
phyla, followed by Actinobacteria and Proteobacteria 
phyla. Other less represented phyla include Verrucomi-
crobia and Fusobacteria.48 The distribution of these 
phyla varies along the gastrointestinal tract, depending 
on the different microenvironments and the nutrient 
availability.49
A healthy microbiota contributes to a healthy host. 
Indeed, microbiota not only plays a fundamental role 
in the metabolism of nutrients and drugs but it also 
contributes to the development and maintenance of 
the intestinal mucosal barrier integrity; additionally, 
it participates in the immune system regulation and 
defence against pathogens.6 7
The relationship between dysbiosis and several diseases 
was robustly established; for example, in periodontal 
disease,50 cancer,51 obesity,52 53 diabetes54 55 and chronic 
fatigue syndrome.56
Pieces of evidence on dysbiosis both in SpA and in IBD 
were also found, which would suggest a link between 
these two inflammatory diseases. For instance, germ- 
free rats HLA- B27 + not only developed gut inflamma-
tion but also joints inflammation after recolonisation.57 
While the effect of some drugs on microbiota, such as 
metphormine, Proton- pump inhibitor (PPI) and anti-
biotics are well known, poor data are available on TNFi.
Since the efficacy of these drugs on SpA and IBD has 
been widely demonstrated, a dramatic improvement in 
inflammatory parameters both in the acute phase index 
(CRP, ESR) and in faecal calprotectin is not surprising.
The aim of our study was to check microbiota modi-
fication after TNFi in a population affected by entero-
pathic arthritis. While some data are available on IBD 
or SpA alone, no literature data exist on this cluster of 
patients. TNFi can have an impact on disease improve-
ments not only by modifying the intestinal permea-
bility but also with a direct action on the microbiota. 
For instance, animal models of PG- induced arthritis 
showed an impaired abundance on three of the most 
representative phyla and TNFi treated animals did not; 
TNFi was able to restore the relative abundance of such 
species, including Lactobacillus and Clostridium.30Ad-
ditionally, a decrease in the major phyla of Firmicutes, 
in particular Faecalibacterium prausnitzii and Clostridium 
leptum species in both SpA and IBD,20 as well as an 
increase of Firmicutes to Gammaproteobacteria has 
Table 3 Univariate analysis to evaluate the association 
between clinimetric variables (covariates) and the delta (T6- 
T0) of relevant microbiota variables (outcome)
Variable
Lachnospiraceae Coprococcus
Coeff P value Coeff P value
Faecal calprotectin −0.003 0.408 −0.000 0.413
CRP −0.157 0.540 −0.099 0.033
ESR 0.062 0.652 −0.022 0.409
VAS pain −0.044 0.783 0.002 0.946
VAS disease −0.028 0.868 0.013 0.679
HAQ 1.717 0.774 1.208 0.287
BASDAI 2.669 0.507 −0.512 0.560
CDAI −1.366 0.062 0.017 0.867
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
CDAI, Clinical Disease Activity Index; CRP, C reactive protein; 
ESR, erythrocyte sedimentation rate; HAQ, Health Assessment 
Questionnaire; VAS, Visual Analogue Scale.
Table 4 Univariate analysis to evaluate the association between the delta (T6- T0) of relevant microbiota variables (covariates) 
and the IBD success/SpA improvement (outcome)
Variable
IBD success SpA improvement
Exp (Coeff) P value Exp (Coeff) P value
Delta Lachnospiraceae 1.053 0.201 0.925 0.100
Delta Coprococcus 1.412 0.234 1.251 0.394
IBD, inflammatory bowel diseases; SpA, spondyloarthritis.
Figure 3 Determination of alpha diversity at the class 
level assessed by the Shannon- Weiner index. Plot of alpha 
diversity against patients at basal (T0, blue) and after 6 
months of treatment (T6, red); a comparison between 
non- responder patients (NR, line) and responder patients 
(R, dots) is also shown both at T0 and T6. Alpha diversity 
was calculated using the Shannon- Wiener Diversity Index 
(Eq. 2); the index for patients at T0 is significantly different 
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been observed in CD.58 Therefore, we first investigated 
the microbiota composition before and after treatment 
at the taxonomic levels (phylum, order, family, genus 
and species), by comparing the faecal samples before 
and after 6 months of TNFi (adalimumab or inflix-
imab) therapy. Focusing on microbiota at the phylum 
level, we observed a reduction of Proteobacteria from 
12.6 (3.4–23.3) to 4.6 (2–6.9), which is consistent with 
literature despite the absence of statistical significance 
(p=0.09). Similarly, we ascertained the same trend 
for the Gammaproteobacteria class (Proteobacteria 
phylum) with a reduction from 10.8 (0–22.8) to 1.8 
(0–6, p=0.09); contrarily, we spot an increase in the 
Clostridia class (Firmicutes phylum), which raised 
from 34 (18.9–47.2) to 42.2 (34.3–52.1, p=0.08). These 
results are consistent with the increase of Firmicutes/
Proteobacteria ratio in IBD patients and seem to indi-
cate a shift versus eubiosis after TNFi.
In the overall Lachnocpiraceae family, the gut micro-
biota showed a discordant trend between SpA and IBD, 
as it increased in the former and reduced in the latter. 
However, two genera of the Lachnocpiraceae family 
shared a similar trend between SpA and IBD; indeed, 
both in SpA and IBD, the Ruminococcus gnavus genus 
increased and the Roseburia genus decreased.59 From 
the analysis at the family level, we observed a significant 
increase of the members of the Lachnospiraceae family, 
which switched from 17.1 (9.2–21.1) to 26.5 (20–29.1, 
p=0.04); of particular interest was the Coprococcus 
genus, which switched from 0 (0–1.6) to 2.8 (0–4, 
p=0.003). Our data again would suggest an impact of 
TNFi on gut microbiota (figure 2).
Literatures reports on the microbiotic population 
trends of SpA and IBD are often conflicting. In some 
cases, the population trend decreases in SpA and grows 
in IBD; in other cases, the population trend increases 
in SpA and decreases in IBD; in still other cases, the 
population trend in SpA is very similar to that in IBD.
In our study, the correct interpretation of results can 
be further complicated as, in some cases, samples were 
taken from patients affected both by SpA and IBD. 
Although, a typical dysbiosis in our cohort should be 
more similar to the IBD dysbiosis—which might indi-
cate a greater impact of IBD than SpA on the micro-
biota of these patients—detected trends in SpA and 
IBD did not demonstrate a full statistical significance; 
we also did not identify any known bacterial alteration 
in IBD.
We discovered a significative decrease of the alpha 
diversity determined using the Shannon- Weiner index 
in the class subgroup between T0 and T6, but these 
findings have not been confirmed by the Simpson 
index (the best index to use with a small sample size). 
As to the evaluation of beta diversity, we did not spot 
differences between patients at T0 and T6 and between 
responders and non- responders.
Our data are consistent with findings from the Aden 
and colleagues study, in which two groups of patients 
affected by IBD or rheumatic diseases were treated with 
TNFi. They discovered that the treatment restored the 
microbiota with an increase in the alpha and beta diver-
sity only for IBD patients; no differences were identi-
fied between responders and not responders.32
Another study concluded that the response to TNFi 
was affected by high disease activity and unstable 
microbiota composition, and patients with reduced 
biodiversity at baseline were more likely to fail the 
TNFi treatment. TNFi abolished the differences among 
patient groups, suggesting that the treatment can 
Figure 4 Determination of the alpha diversity between 
non- responders at the class level assessed by the Shannon- 
Weiner index. Plot of the alpha diversity against non- 
responder patients at basal (T0, blue) and after 6 months 
of treatment (T6, red). Alpha diversity was calculated using 
the Shannon- Wiener Diversity Index (Eq. 2); the index for 
patients at T0 is significantly different from those at T6 (two- 
tailed t- test with unequal variance, p value=0.0053).
Figure 5 Determination of alpha diversity at the class 
level assessed by Simpson index. Plot of alpha diversity 
against patients at the basal (T0, blue) and after 6 months of 
treatment (T6, red); a comparison between non- responders 
(NR, line) and responders (R, dots) is also shown both at T0 
and T6. Alpha diversity was calculated using the Simpson’s 
Diversity Index (equation 1); the index for patients at T0 is not 
significantly different from those at T6 (two- tailed t- test with 
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restore the microbiota, which happens independently 
to the clinical response.33 As a consequence of this, we 
performed further analysis to verify the impact of the 
inflammatory status on the change of the microbiota 
and check the relationship between the movement of 
the microbiota and the course of the disease. The univar-
iate analysis showed that the CRP trend—a parameter 
of inflammation both for SpA and IBD—is consistent 
with the Coprococcus trend; this would confirm the 
hypothesis that the TNFi therapy tends to restore the 
intestinal eubiosis, by decreasing inflammation. We 
did not spot differences between responders and not 
responders, suggesting that TNFi can restore faecal 
microbiota and independently to clinical response.32
The sample size of our population was small, which 
heavily affected the power of our statistical analysis.
Our study did not compare the intestinal microbiota 
of patients with that of healthy people and, there-
fore, it does not establish the nature of the dysbiosis, 
which might play a key role in the pathogenesis of SpA. 
Furthermore, we did not compare groups of patients 
treated by TNFi or other concomitant treatment with 
those drugs regularly used by patients as maintenance 
therapy (such as mesalazine, azathioprine, steroids 
and antibiotics)60; thus, we cannot strongly affirm that 
modifications of microbiota are related to TNFi. To 
partially solve this bias, patients maintained the same 
therapy before and during the study period; moreover, 
all patients were treated with infliximab or adalimumab 
(etanercept was excluded). These drugs in vitro simi-
larly mediate complement- dependent cytotoxicity and 
antibody- dependent cell- mediated cytotoxicity; they 
also affect in the same manner the proportion of cells 
undergoing apoptosis and the level of granulocyte 
degranulation.61
We analysed microbiota in faecal samples, which 
were used as a surrogate for the entire gut microflora. 
Although it is well known that the composition and 
function of the faecal microflora differ from that of the 
mucosal microflora48 and it also includes microbiota 
and virota, the evaluation of stool samples is currently 
the easiest way to assess intestinal microbiota and it 
allows the evaluation of the microflora from the entire 
gut tract.
Our study is based on 16S rDNA sequencing, which 
allowed us to investigate only bacteria and exclude 
the virobiota, the mycobiota and eucaryota inhabiting 
intestinal tract and playing a consistent role in the phys-
iopathology of several diseases.62
We included into the study only patients with a 
typical Mediterranean diet, but we did not perform any 
specific evaluation on the diet; for instance, we did not 
determine the percentages of carbohydrates, fats and 
proteins intake, which might have affected the results.63
Although enteropathic arthritis is a well- known noso-
logical entity, there are not clinimetric systems to eval-
uate the progress of this disease; therefore, the trend of 
both IBD and arthritis have been ascertained separately. 
Furthermore, literature concerning dysbiosis in these 
two pathologies often differs, leading to a distortion of 
our results.
Despite these limits and independently of the 
achievement of clinical success, our results unequivo-
cally reveal a modification of the microbiota towards 
eubiosis related to TNFi. Based on this, the microbiota 
could play a key role in targeted therapies in the future.
CONCLUSIONS
Our study is a proof of concept study, which has explored 
for the first time the modification of microbiota composi-
tion towards eubiosis in relationship with the TNFi treat-
ment. Our study would indicate an association of TNFi 
with the decrease of Proteobacteria and with the increase 
of Lachnospiraceae and Coprococcus. The study data 
would support the hypothesis the TNFi therapy, by 
decreasing inflammation, tends to restore the intestinal 
eubiosis. Our study is characterised by some limitations, 
including the small number of patients under analysis 
and the absence of a control, which prevents from a 
definitive conclusion; yet, it can be considered a starting 
point for future examinations on this topic.
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